Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial

Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial

Background: De-escalating anthracycline is gaining popularity for breast cancer patients. We aim to evaluate the non-inferiority of an anthracycline-free or short-term regimen to the standard anthracycline-based regimen for operable patients with human epidermal growth factor receptor 2 (HER2)-negat...

Full description

Bibliographic Details
Main Authors: Ke-Da Yu, Xi-Yu Liu, Li Chen, Miao Mo, Jiong Wu, Guang-Yu Liu, Gen-Hong Di, Claire Verschraegen, Daniel G. Stover, Zhi-Gang Zhuang, François Bertucci, Armando Orlandi, Jie Wang, Giuseppe Lippi, Ke-Jin Wu, Mohammed A. Osman, Lei Fan, Zhi-Ming Shao
Format: Article
Language:English
Published: Elsevier 2021-06-01
Series:The Lancet Regional Health. Western Pacific
Online Access:http://www.sciencedirect.com/science/article/pii/S2666606521000675

Internet

http://www.sciencedirect.com/science/article/pii/S2666606521000675

Similar Items